Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study

被引:43
作者
Jovanovic, Dragana [1 ,2 ]
Milenkovic, Marina Roksandic [1 ,2 ]
Stevuljevic, Jelena Kotur [3 ]
Markovic, Jelena [1 ]
Ceriman, Vesna [1 ]
Kontic, Milica [1 ,2 ]
Trifunovic, Vesna Skodric [1 ,2 ]
机构
[1] Univ Hosp Pulmonol, Clin Ctr Serbia, Koste Todorovica 26, Belgrade 11000, Serbia
[2] Univ Belgrade, Sch Med, Belgrade, Serbia
[3] Univ Belgrade, Dept Med Biochem, Fac Pharm, Belgrade, Serbia
关键词
Idiopathic pulmonary fibrosis (IPF); membrane PD-L1 expression; soluble PD-L1; DEATH LIGAND 1; PROGNOSTIC-SIGNIFICANCE; TISSUE-REPAIR; LUNG-CANCER; MACROPHAGES; CELL; PATHWAY; PATHOGENESIS; HOMEOSTASIS; ACTIVATION;
D O I
10.21037/jtd.2018.11.16
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Idiopathic pulmonary fibrosis (IPF) has common risk factors with cancer and significant similarities in the pathobiology process, both diseases having poor outcomes. Immune checkpoint PD-L1 has become the target of checkpoint inhibitory therapy that unleashes antitumor T cells and has revolutionized cancer treatment. This is a pilot study exploring membrane immune checkpoint PD-L1 expression in human IPF lung tissue samples and its soluble form, soluble PD-L1 (sPD-L1) plasma concentrations in IPF patients, in order to investigate potential role of PD-L1 as an IPF biomarker. Methods: Twelve human IPF lung tissue samples (formalin-fixed, paraffin-embedded) obtained by surgical biopsy, have been tested for PD-L1 expression by PD-L1 IHC 22C3 pharmDx assay, while plasma samples for examination of sPD-L1 forms, PD-L1 (B7-H1/CD274) blood concentration, originated from 23 patients with IPE who did not undergo surgical biopsy. Results: Membrane PD-L1 expression in IPF lung tissue samples was positive to overexpression of PD-L1 in 9 samples out of 12. Only very few cells in the interstitium have shown a discrete PD-L1 expression, but not of a membrane type. As for sPD-L1 forms, we have found elevated concentrations of sPD-L1 in the serum of IPF patients 314.3 ng/L (117.7-483.1 ng/L), significantly higher compared with healthy control group 91.0 ng/L (52.4-119.7 ng/L), P<0.01. Conclusions: For IPF with PD-L1 expression on alveolar macrophages, further studies are necessary to elucidate this phenomenon. Serum sPD-1/PD-L1 is easily detected in clinical practice and should be further evaluated as a potential prognostic or/and predictive biomarker in IPF.
引用
收藏
页码:6660 / 6669
页数:10
相关论文
共 50 条
  • [11] Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors
    Fan, Yangwei
    Ma, Ke
    Wang, Chuying
    Ning, Jing
    Hu, Yuan
    Dong, Danfeng
    Dong, Xuyuan
    Geng, Qianqian
    Li, Enxiao
    Wu, Yinying
    ONCOTARGETS AND THERAPY, 2016, 9 : 6075 - 6082
  • [12] Variability of PD-L1 expression in mastocytosis
    Hatch, Ellen W.
    Geeze, Mary Beth
    Martin, Cheyenne
    Salama, Mohamed E.
    Hartmann, Karin
    Eisenwort, Gregor
    Blatt, Katharina
    Valent, Peter
    Gotlib, Jason
    Lee, Ji-Hyun
    Chen, Lu
    Ward, Heather H.
    Lidke, Diane S.
    George, Tracy I.
    BLOOD ADVANCES, 2018, 2 (03) : 189 - 199
  • [13] PD-L1 Expression in Lung Cancer
    Yu, Hui
    Boyle, Theresa A.
    Zhou, Caicun
    Rimm, David L.
    Hirsch, Fred R.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (07) : 964 - 975
  • [14] PD-L1 expression in extrahepatic cholangiocarcinoma
    Walter, Dirk
    Herrmann, Eva
    Schnitzbauer, Andreas A.
    Zeuzem, Stefan
    Hansmann, Martin Leo
    Peveling-Oberhag, Jan
    Hartmann, Sylvia
    HISTOPATHOLOGY, 2017, 71 (03) : 383 - 392
  • [15] Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
    Zhang, Jie
    Gao, Jing
    Li, Yanyan
    Nie, Jun
    Dai, Ling
    Hu, Weiheng
    Chen, Xiaoling
    Han, Jindi
    Ma, Xiangjuan
    Tian, Guangming
    Wu, Di
    Shen, Lin
    Fang, Jian
    THORACIC CANCER, 2015, 6 (04) : 534 - 538
  • [16] PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay
    Cimadamore, Alessia
    Massari, Francesco
    Santoni, Matteo
    Lopez-Beltran, Antonio
    Cheng, Liang
    Scarpelli, Marina
    Montironi, Rodolfo
    Moch, Holger
    CURRENT DRUG TARGETS, 2020, 21 (16) : 1664 - 1671
  • [17] Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression
    Shigemori, Tsunehiko
    Toiyama, Yuji
    Okugawa, Yoshinaga
    Yamamoto, Akira
    Yin, Chengzeng
    Narumi, Aya
    Ichikawa, Takashi
    Ide, Shozo
    Shimura, Tadanobu
    Fujikawa, Hiroyuki
    Yasuda, Hiromi
    Hiro, Junichiro
    Yoshiyama, Shigeyuki
    Ohi, Masaki
    Araki, Toshimitsu
    Kusunoki, Masato
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (03) : 876 - 883
  • [18] The clinical significance of soluble PD-1 and PD-L1 in lung cancer
    Abu Hejleh, Taher
    Furqan, Muhammad
    Ballas, Zuhair
    Clamon, Gerald
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 143 : 148 - 152
  • [19] EVALUATION OF SPATIAL PD1 AND PD-L1 EXPRESSION IN INFLAMMATORY BOWEL DISEASE SAMPLES - A PILOT STUDY
    Szczepaniak, Kinga
    Paskal, Wiktor
    Kusmierczyk, Zofia
    Wejman, Jaroslaw
    Ostrowska, Joanna
    Tarnowski, Wieslaw
    Wlodarski, Pawel
    POLISH JOURNAL OF PATHOLOGY, 2022, 73 (01) : 50 - 59
  • [20] Smoking Is Associated With Low Levels of Soluble PD-L1 in Rheumatoid Arthritis
    Wasen, Caroline
    Erlandsson, Malin C.
    Bossios, Apostolos
    Ekerljung, Linda
    Malmhall, Carina
    Silfversward, Sofia Toyra
    Pullerits, Rille
    Lundback, Bo
    Bokarewa, Maria I.
    FRONTIERS IN IMMUNOLOGY, 2018, 9